Related Experiment Video
Updated: Mar 14, 2026
09:43
Synthesis of Immunotargeted Magneto-plasmonic Nanoclusters
Published on: August 22, 2014
15.7K
Nanohybride Materials Based on Magnetite-Gold Nanoparticles for Diagnostics of Prostate Cancer: Synthesis and In
A E Machulkin1,2, A S Garanina3, O A Zhironkina4
1Laboratory of Tissue-Specific Ligands, Faculty of Chemistry, M. V. Lomonosov Moscow State University, Moscow, Russia. alekseymachulkin@rambler.ru.
Bulletin of Experimental Biology and Medicine
|October 6, 2016
Summary
Researchers developed novel nanoparticles targeting prostate specific membrane antigen (PSMA) for cancer imaging. These PSMA-targeted nanoparticles selectively bind to prostate cancer cells, showing potential for advanced magnetic-resonance imaging applications.
Area of Science:
- Nanotechnology
- Biomedical Engineering
- Oncology
Background:
- Prostate cancer diagnosis remains a challenge.
- Targeted therapies require specific biomarkers.
- Prostate specific membrane antigen (PSMA) is a key biomarker in prostate cancer.
Purpose of the Study:
- To synthesize and characterize novel nanoparticles for prostate cancer detection.
- To evaluate the targeting specificity of these nanoparticles.
- To explore their potential in magnetic-resonance imaging (MRI).
Main Methods:
- Synthesis of fluorescence-conjugated, modified magnetite-gold nanoparticles.
- Ligand modification with prostate specific membrane antigen (PSMA).
- In vitro binding assays using PSMA-positive (LNCaP) and PSMA-negative (PC-3) prostate cancer cell lines.
Main Results:
- The synthesized nanoparticles and conjugate demonstrated selective binding to LNCaP cells.
- Minimal interaction was observed with PC-3 cells, confirming specificity.
- Successful conjugation and modification of nanoparticles were confirmed.
Conclusions:
- The developed PSMA-targeted nanoparticles exhibit high specificity for prostate cancer cells.
- These nanoparticles hold significant promise for tissue-specific MRI in prostate cancer.
- Further research can advance nanoparticle-based diagnostics.
